WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 23-May-2016 (Data received as of 20-May-2016)
Next overall update Fall 2016
2015 data are provisionary
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 9'8801 Infant (under 12 months) mortality rate: 72
GDP / capita (US$): 17'6031 Child (under 5 years) mortality rate: 82

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 5'851  5'612  5'287  4'924  4'592  3'235  2'703  2'605 
Births 86  82  78  73  68  62  68  78 
Surviving infants 85  81  77  72  67  61  66  75 
Pop. less than 5 years 461  435  387  334  295  305  311  366 
Pop. less than 15 years 1'404  1'350  1'264  1'167  1'085  927  923  1'017 
Female 15-49 years 1'630  1'556  1'459  1'352  1'250  885  688  626 

Number of reported cases

(Click for retrospective incidence data for Lebanon)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart
  39  112  1'761 
Mumps
ChartChart
  1'496  14  12  12  23 
Pertussis
ChartChart
  53  58  53 
Polio*
ChartChart
 
Rubella
ChartChart
  18  27 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Lebanon)
Vaccine year result method % card seen                                                
BCG         
DTP1 2008  84  MICS   55  93  96  99*  99  98  93 
DTP3 2008  72  MICS   55  91  97  98  95  95  90  82 
DTP4          91 
IPV1          92  98 
HepB_BD          99*  99*  99*  94  99  90 
HepB3 2008  72  MICS   55  91  97  98  95  95  70 
Hib3 2008  72  MICS   55  91  97  98  95  95 
JapEnc         
MCV1          91  98  99  98  98  90  39 
MCV2          68  69  79  88  86  87 
PCV1         
PCV3         
Pol3 2008  74  MICS   55  90  97  99*  96  96  90  82 
Rota1         
RotaC         
Rubella1          91  98  99  98  98 
TT2plus         
PAB         
VAD1         
YFV 2003  50  PAPFAM   62 
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Lebanon)
DTP1
ChartChart
  84  84  84  84  90  94  17 
DTP3
ChartChart
  81  81  81  81  83  82 
HepB3
ChartChart
  81  81  81  81  83 
HepB_BD
ChartChart
  94  94  94  94  90 
Hib3
ChartChart
  81  81  81  81 
MCV1
ChartChart
  79  79  79  79  71  61 
MCV2
ChartChart
  75  75  75  75  56 
PCV3
ChartChart
 
Pol3
ChartChart
  75  75  75  75  83  82 
RotaC
ChartChart
 

Number of districts in the country 26  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DT Yes children having problem/pertussis
DTwP 4-5 years; Yes
DTwPHibHepB 2, 4, 6, 18 months; Yes
HepB birth; Yes
IPV 2 months; Yes
Influenza Yes Children, elderly, chronic illness, pregnant women, health care workers, Haj or other travellers
MMR 12, 18 months; Yes
Measles 9 months; Yes
MenACWY Yes Haj pilgrimage
OPV 4, 6, 18 months; 4-5, 10-12, 16-18 years; Yes
Pneumo_conj 4, 6, 12 months Yes From June 2015
Td 10-12, 16-18 years; Yes
VitaminA 9 months; Yes

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2010-2015  2010-2014  2010-2014  2010-2014  2010-2014  2010- 2014  2009-2013 
Nº of districts with microplans that include activities to raise immunization coverage number 26  25  20  18  17  15  25 

System performance

Total Nº districts in country number 26  26  26  26  26  26  26 
Nº districts with DTP3 coverage >=80% number 26  26  26  26  25  26 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  96  100 
Nº districts with measles (MCV1) coverage >=95% number 20  18  11  12 
% of districts with MCV1 coverage >=95% From 0 to 100% 27  77  69  23  35  42  46 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 100  100  100    100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.